A five-day course of the antiviral drug remdesivir sped recovery in moderately ill patients with pneumonia from Covid-19, drugmaker Gilead Sciences announced in a statement Monday. John Bonifield and Jacqueline Howard write for CNN that this is more evidence that the drug can help patients, however outside experts are not calling this a “game changer” quite yet. Coronavirus patients who were hospitalized, but not sick enough to need oxygen from a ventilator, were more likely to recover after a five-day course of remdesivir than those given the current standard of care alone, Gilead said.